Editorial
Development of passive immunity against SARS-CoV-2 for management of immunodeficient patients—a perspective

https://doi.org/10.1016/j.jaci.2020.04.043Get rights and content

Key words

COVID-19
immunodeficiency
passive immunity
plasma therapy
IVIG
mAb

Cited by (0)

This work was supported by the Swedish Research Council and the European Commission Horizon 2020 program (grant no. 101003650-ATAC).

Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.

View Abstract
© 2020 American Academy of Allergy, Asthma & Immunology